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Abstract
Background: Clinical trials are important for patients, for researchers and for companies. One of the major
bottlenecks is patient recruitment. This task requires the matching of a large volume of information about the patient
with numerous eligibility criteria, in a logically-complex combination. Moreover, some of the patient’s information
necessary to determine the status of the eligibility criteria may not be available at the time of pre-screening.
Results: We showed that the classic approach based on negation as failure over-estimates rejection when
confronted with partially-known information about the eligibility criteria because it ignores the distinction between a
trial for which patient eligibility should be rejected and trials for which patient eligibility cannot be asserted. We have
also shown that 58.64% of the values were unknown in the 286 prostate cancer cases examined during the weekly
urology multidisciplinary meetings at Rennes’ university hospital between October 2008 and March 2009.
We propose an OWL design pattern for modeling eligibility criteria based on the open world assumption to address
the missing information problem. We validate our model on a fictitious clinical trial and evaluate it on two real clinical
trials. Our approach successfully distinguished clinical trials for which the patient is eligible, clinical trials for which we
know that the patient is not eligible and clinical trials for which the patient may be eligible provided that further
pieces of information (which we can identify) can be obtained.
Conclusions: OWL-based reasoning based on the open world assumption provides an adequate framework for
distinguishing those patients who can confidently be rejected from those whose status cannot be determined. The
expected benefits are a reduction of the workload of the physicians and a higher efficiency by allowing them to focus
on the patients whose eligibility actually require expertise.
Introduction
Patient recruitment is a major focus in all clinical tri-
als. Adequate enrollment provides a base for projected
participant retention, resulting in evaluative patient data.
Identification of eligible patients for clinical trials (from
the principal investigator’s perspective) or identification
of clinical trials in which the patient can be enrolled (from
the patient’s perspective) is an essential phase of clini-
cal research and an active area of medical informatics
research. TheNational Cancer Institute has identified sev-
eral barriers that health care professionals claim in regard
to clinical trial participation [1]. Among those barriers,
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lack of awareness of appropriate clinical trials is frequently
mentioned.
Automated tools that help perform a systematic screen-
ing either of the potential clinical trials for a patient, or
of the potential patients for a clinical trial could overcome
this barrier [2]. Efforts have been dedicated to provide
a uniform access to heterogeneous data from different
sources. The Biomedical Translational Research Infor-
mation System (BTRIS) is being developed at NIH to
consolidate clinical research data [3]. It is intended to sim-
plify data access and analysis of data from active clinical
trials and to facilitate reuse of existing data to answer
new questions. STRIDE [4] is a platform supporting clin-
ical and translational research consisting of a clinical data
warehouse, an application development framework for
building research data management applications and a
© 2013 Dameron et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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biospecimen data management system. The i2b2 frame-
work integrates medical records and clinical research
data [5] and SHRINE [6] handles several sources by pro-
viding a federated query tool for clinical data reposito-
ries. The ObTiMA system relies on OWL and SWRL
to perform semantic mediation between heterogeneous
data sources [7]. Lezcano et al. propose an architec-
ture based on OWL to represent patients data from
archetypes, and on SWRL rules to perform the reason-
ing [8]. Several other efforts have been dedicated to
the formal representation of clinical trials eligibility cri-
teria to support automated reasoning [9]. Weng et al.
performed an extensive literature review [10]. They con-
firmed that although eligibility criteria are usually written
in free text to be human-readble, standard-based com-
putable knowledge representations for eligibility criteria
are necessary to clinical and research tasks. They iden-
tified five key aspects of eligibility criteria representa-
tion, three of which being essential for knowledge-based
representation of eligibility criteria: expression language
for representing eligibility rules, the encoding of eligi-
bility concepts and patient data modeling. Milian et al.
developed a method for automatic formalization of eli-
gibility criteria and comparison of their restrictiveness
[11,12]. Their goal is to support the design of eligibil-
ity criteria, enable their reuse and provide meaningful
suggestions of relaxing them based on previous trials.
They processed eligibility criteria from 300 clinical trials,
and created a library of structured conditions cover-
ing 18% of encountered inclusion and exclusion criteria.
Ross et al. conducted a survey of 1,000 criteria randomly
selected from ClinicalTrials.gov and found that 80% of
them had a significant semantic complexity [13], with
40% involving some temporal reasoning. Tu et al. pro-
posed an approach to convert free text eligibility criteria
into the computable ERGO formalism [14]. O’Connor
et al. developed a solution based on OWL and SWRL
that supports temporal reasoning and bridges the gap
between patients specific data and more general eligibility
criteria [15].
The ASTEC (Automatic Selection of clinical Trials
based on Eligibility Criteria) project aims at automat-
ing the search of prostate cancer clinical trials to which
patients could be enrolled to [16]. It features syntac-
tic and semantic interoperability between the oncologic
electronic medical records and the recruitment deci-
sion system using a set of international standards (HL7
and NCIT), and the inference method is based on
ERGO [17].
The EHR4CR project aims at facilitating clinical trial
design and patient recruitment by developing tools and
services that reuse data from heterogeneous electronic
health records [18]. The TRANSFoRm project has similar
objectives for primary care [19,20].
All these studies on data and criteria representa-
tion, integration and reasoning are motivated by the
requirement to have the necessary information available
at the time of processing the patient’s data, and assume
that somehow, that will be the case.
Missing information that is required for deciding
whether a criterion is met leads to recruitment being
underestimated.
Solutions for circumventing this difficulty consist either
in making assumptions about the undecided criteria, or
in having a pre-screening phase considering a subset of
the criteria for which patient’s data are assumed to be
available.
Bayesian belief networks have been used to address the
former [21] but require a sensible choice of probability
values and may lead to the wrong asumption in particular
cases.
The latter leaves most of the decision task to human
expertise, which provides little added value (if an expert
has to handle the difficult criteria, automatically process-
ing the simple pre-screening ones is only a little weight
off his shoulders) and is still susceptible to the problem of
missing information for the pre-screening criteria.
We propose an OWL design pattern for modeling clin-
ical trial eligibility criteria. This design pattern is based
on the open world assumption for handling missing infor-
mation. It infers whether a patient is eligible or not
for a clinical trial, or if no definitive conclusion can be
reached.
Background
Modeling eligibility criteria
A clinical trial can bemodeled as a pair< (Ii)
n
i=0, (Ej)
m
j=0 >
where (Ii)
n
i=0 is the set of the inclusion criteria, and (Ej)
m
j=0
is the set of the exclusion criteria. All the eligibility crite-
ria from (Ii)
n
i=0 ∪ (Ej)
m
j=0 are supposed to be independent
from one another (at least in the weak sense: the value
of criterion Ck cannot be infered from the combined val-
ues of other criteria). Each criterion can be modeled as
an unary predicate C(p), where the variable p represents
all the information available for the patient. C(p) is true if
and only if the criterion is met.
A patient is deemed eligible for a clinical trial if all the
inclusion criteria and none of the exclusion criteria are
met.
patient eligible⇔
n
∧
i=0
Ii(p) ∧ ¬(
m
∨
j=0
Ej(p)) (1)
Before making the final decision on the list of clinical
trials for which a patient is eligible for, there are interme-
diate pre-screening phases where only the main eligibility
criteria of each clinical trial are considered. Such pre-
screening sessions rely on subsets of (Ii)
n
i=0 and (Ej)
m
j=0,
but the decision process remains the same.
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For the sake of clarity, in addition to the general case,
we will consider a simple clinical trial with two inclusion
criteria I0 and I1, and two exclusion criteria E0 and E1.
patient eligible⇔ I0(p)∧ I1(p)∧¬(E0(p)∨E1(p)) (2)
For example, these criteria could be:
• I0: evidence of a prostate adenocarcinoma;
• I1: absence of metastasis;
• E0: patient older than 70 years old;
• E1: evidence of diabetes.
According to equation 2, a patient would be eligible for
the clinical trial if and only if he has a prostate adenocar-
cinoma and has no metastasis and is neither older than 70
years old nor suffers from diabetes.
Because of De Morgan’s laws, equation 1 is equivalent
to:
patient eligible⇔ (
n
∧
i=0
Ii(p)) ∧ (
m
∧
j=0
¬Ej(p)) (3)
Even though equation 1 and equation 3 are logically
equivalent, the latter is often preferred because it is an
uniform conjunction of criteria. Note that the negations
in front of the exclusion criteria are purely formal, as
both inclusion and exclusion criteria can represent an
asserted presence (e.g. prostate adenocarcinoma for I0 or
of diabetes for E1) or an asserted absence (e.g. metastasis
for I1).
For our example:
patient eligible⇔ I0(p)∧ I1(p)∧ (¬E0(p))∧ (¬E1(p))
(4)
According to equation 3, a patient would be eligible for
the clinical trial if and only if he has a prostate adenocarci-
noma and has no metastasis and is not older than 70 years
old and does not suffer from diabetes.
The problem of unknown information
Distinction between the patients that we know are not
eligible and those that we do not know if they are eligible
When a part of the information necessary for determining
if at least one criterion is met is unknown, the conjunction
of equation 3 can never be true. This necessarily makes
the patient not eligible for the clinical trial, whereas the
correct interpretation of the situation is that the patient
cannot be proven to be eligible. This is different from
proving that the patient is not eligible, and indeed, in real-
ity the patient can sometimes be included by assuming the
missing values (cf. next section).
For our fictitious clinical trial, we consider a population
of nine patients covering all the combinations of “True”,
“False” or “Unknown” for the inclusion criterion I1 and
the exclusion criterion E1. Table 1 presents the value of
Table 1 Differences between the logical evaluation of the
criteria conjunction and the correct inclusion decision
when only a portion of the necessary information is
known: evaluation of equation 4 and correct inclusion
decision for all the possible values of I1 and E1, with
possibly unknown information
Patient I0 I1 E0 E1 I0 ∧ I1∧ Decision
¬E0 ∧ ¬E1
p0 T T F T F Exclude
(E1)
p1 T T F F T Include
p2 T T F ? F Propose
cannot (assume ¬E1)
assert ¬E1
p3 T F F T F Exclude
(both ¬I1 and E1)
p4 T F F F F Exclude
(¬I1)
p5 T F F ? F Exclude
(¬I1)
p6 T ? F T F Exclude
(E1)
p7 T ? F F F Propose
cannot (assume I1)
assert I1
F
p8 T ? F ? cannot Propose
assert I1
cannot (assume both
assert ¬E1 I1 and ¬E1)
equation 4 and correct inclusion decision for the nine
combinations. Among the five patients (p2, p5, p6, p7 and
p8) for which at least a part of the information is unknown,
three (p2, p7 and p8) illustrate a conflict between the value
of equation 4 and expected inclusion decision. A strict
interpretation of equation 4 leads to the exclusion of the
eight patients:
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• for three of them (p0, p3 and p4), all the information
is available;
• for two of them (p5 and p6), some information is
unknown, but the available information is sufficient
to conclude that the patients are not eligible;
• for the three others (p2, p7 and p8), however, the
cause of rejection is either because one of the
inclusion criteria cannot be proven (I1 for p7 and p8)
or because one of the exclusion criteria cannot be
proven to be false (E1 for p2 and p8).
In the case of unknown information, equation 3 alone is
not enough to make the distinction between the patients
we know are not eligible (the first two categories, so this
also includes patients for whom a part of the information
is unknown) and those we do not know if they are eligible
(the third category). This is a problem because patients
from the first two categories should be excluded from the
clinical trial, whereas those from the third category should
be considered for inclusion.
Assuming values for criteria
Currently, the case of each patient diagnosed with can-
cer is examined in a multidisciplinary meeting (MDM)
gathering experts (oncologists, pathologists, surgeons,...).
The goal is to determine collectively the best therapeutic
strategy for the patient, including consideration of poten-
tial inclusion into clinical trials. This preliminary stage is
called pre-screening because it takes place before obtain-
ing the patient’s informed consent (i.e., before enroll-
ment). It mainly relies on retrospective data coming from
the patient health record. At this point, all the information
necessary for determining the status of each inclusion and
exclusion criteria may not be available, but the rationale is
to focus on the clinical trials for which the patient may be
eligible for. It should be noted that the missing items may
differ between patients. One solution could be to assume
the values of the unknown criteria in order to go back to a
situation where inclusion or exclusion could be computed
using equation 3.
In this case:
• inclusion criteria for which the available information
is not sufficient to compute the status are considered
to be met;
• exclusion criteria for which the available information
is not sufficient to compute the status are considered
not to be met.
Therefore, in the case where the available information is
not sufficient to compute the status of a criterion, a differ-
ent status is assumed depending on whether the criterion
determines inclusion or exclusion.
Referring to our fictitious clinical trial, the lack of infor-
mation about the absence of metastasis would lead to the
assumption that I1 is true, whereas the lack of informa-
tion about diabetes would lead to the assumption that E1
is false.
This situation raises several issues:
• a different status is assumed depending on whether
the criterion determines inclusion or exclusion;
• the assumed status depends on the nature of the
criterion (i.e. inclusion or exclusion) and not on its
probability;
• one has to remember that the value for at least a
criterion has been assumed in order to qualify the
inferred eligibility (adamant for p0 or p1 vs “under the
assumption that...” for p2, p7 and p8);
• this qualification can be difficult to compute (the
status of E1 is unknown for both p2 and p5, but p5
can be confidently excluded whereas p2 can be
included assuming E1).
The extent of the missing information problem
To determine the extent of the missing information prob-
lem, we analyzed the 286 prostate cancer cases examined
during the weekly urology multidisciplinary meetings at
Rennes’ university hospital between October 2008 and
March 2009. This involved 252 patients: 25 of them
were examined during two different MDM, and 5 were
examined during three different MDM. Before the MDM,
the patient’s data are collected in a form with 65 fields.
The form supports the distinction between known and
unknown values (e.g. for “antecedent of neoplasm”, the
possible answer are “yes”, “no”, “not specified”).
Overall, 11,323 values (60.90%) were not specified. On
average, for each case studied in a MDM, 39.6 fields
(among 65) had an unknown value.
All of the 286 cases studied had at least some of the 65
fields with an unknown value. Indeed, the case with the
most fields filled still missed 22 of them.
59 fields (90.77% of 65) had a missing value in at least
one of the 286 cases. The six fields that were systemat-
ically filled were: the patient identifier, the MDM date,
the patient’s birth date, the patient’s gender, the tumor
anatomic site and the primary histological type.
During this period, 4 clinical trials related to prostate
cancer running at Rennes Comprehensive Cancer Centre
were considered during the MDM. Table 2 presents the
composition of the clinical trials fields and their propor-
tion of missing information. It shows that for each clinical
trial, all the patients had at least one missing field that pre-
vented formula 3 to be true (regardless of the values of the
known fields).
Methods
We propose an OWL design pattern for modeling clinical
trial eligibility criteria. We then explain how the reasoning
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Table 2 Importance of unknown information during pre-screening for the four clinical trials of interest: importance of
unknown information during pre-screening for the four clinical trials of interest
CT1 CT2 CT3 CT4
Nb inclusion fields 15 19 16 10
Nb exclusion fields 10 9 8 11
Nb common fields 3 0 2 3
Missing values 50.06% 61.72% 56.52% 42.99%
Nb patients with all inclusion fields known 0 0 1 1
Nb patients with all exclusion fields known 4 3 0 1
Nb patients with all fields known 0 0 0 0
Nb eligible patients 30 23 6 2
unfolds using the fictitious clinical trial from Table 1. We
validate our approach by verifying if the inferred outcome
corresponds to the expected value from Table 1. We eval-
uate our approach on two of the four clinical trials related
to prostate cancer and the 286 cases mentioned in the
previous section. This allows us to quantify the impact of
missing information on inclusion rates, as we have seen
that in some cases, even partially-known information can
lead to certain rejection.
We reused anonymized data from the patients’ medical
records and did not conduct any experimental study. The
study was approved by Rennes’ Hospital ethics evaluation
committee institutional review board under the reference
13-26 (2013).
Results
Eligibility criteria design pattern
• for each criterion, create a class C_i (at this point, we
do not care if it is an inclusion or an exclusion
criteria, or both) and possibly add a necessary and
sufficient definition representing the criterion itself
(or use SWRL);
• for each criterion, create a class Not_C_i defined as
Not_C_i ≡ Criterion ⊓¬ C_i. This process can
be automated;
• for each clinical trial, create a class Ct_k
(placeholder);
• for each clinical trial, create a class Ct_k_include
as a subclass of Ct_k with a necessary and sufficient
definition representing the conjunction of the
inclusion criteria and of the exclusion criteria (cf.
equation 3) (Ct_k_include ≡
n
⊓
i=0
I_i ⊓
m
⊓
j=0
Not_E_j);
• for each clinical trial, create a class Ct_k_exclude
(placeholder) as a subclass of Ct_k;
• for each clinical trial, create a class
Ct_k_exclude_at_least_one_exclusion_
criterion as a subclass of
Ct_k_exclude with a necessary and sufficient
definition representing the disjunction of the
exclusion criteria
(Ct_k_exclude_at_least_one_exclusion_
criterion ≡
m
⊔
j=0
E_j);
• for each clinical trial, create a class
Ct_k_exclude_at_least_one_failed_
inclusion_criterion as a subclass of
Ct_k_exclude with a necessary and sufficient
definition representing the disjunction of the negated
inclusion criteria
(Ct_k_exclude_at_least_one_failed_
incl_criterion ≡
n
⊔
i=0
Not_I_i);
• represent the patient’s data with instances (Figures 1
and 2). For the sake of simplicity, we will make the
patient an instance of as many C_i as we know he
matches criteria, and as many Not_C_j classes as we
know he does not match criteria, even if this is
ontologically questionable (a patient is not an
instance of a criterion). How the patient’s data are
reconciled with the criteria by making the patient an
instance of the criteria is not specified here: it can be
manually, or automatically with OWL necessary and
sufficient definitions or SWRL rules for the C_i and
Not_C_j classes.
Reasoning
If all the required information is available, after classifica-
tion, for each criterion the patient will be an instance of
each C_i or Not_C_i, and therefore will also be instan-
tiated as either Ct_k_include (like p1 in Figure 3),
Ct_k_exclude_at_least_one_exclusion_criterion
or Ct_k_exclude_at_least_one_failed_inclusion_
criterion (so at least we are doing as well as the other
systems).
If not all the information is available, because of the
open world assumption, there will be some criteria for
which the patient will neither be classified as an instance
of C_i nor of Not_C_i (e.g. in Figure 2, p2 is neither
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Figure 1 A patient for whom all the information is available.
an instance of E_1 nor of Not_E_1), so he will not
be classified as an instance of Ct_k_include either.
However, the patient may be classified as an instance of
Ct_k_exclude_at_least_one_exclusion_criterion
or of Ct_k_exclude_at_least_one_failed_inclusion_
criterion. As both are subclasses of Ct_k_exclude,
we will conclude that the patient is not eligible for
the clinical trial. We will even know if it is because
he matched an exclusion criterion (like p0, p3 and p6
in Figure 4), because he failed to match an inclusion
Figure 2 A patient for whom some information is unknown (here about E1).
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Figure 3 The class modeling clinical trial inclusion after classification (here patient p1 can be included).
criterion (like p3, p4 and p5 in Figure 5), or both
(like p3).
If the patient is neither classified as an instance of
Ct_k_include nor of Ct_k_exclude (or its sub-
classes), then we will conclude that the patient can be
considered for the clinical trial, assuming the missing
information will not prevent it (like p2, p7 and p8, who do
not appear in Figures 3, 4 and 5, consistently with Table 1.
By retrieving the criteria for which the patient is neither
an instance of C_i nor of Not_C_i, we will know which
information is missing.
Validation
We modeled our fictitious clinical trial as well as the nine
combinations of values (Additional file 1). All the results
were identical to the decision of Table 1.
Evaluation
We evaluated our model on the first (Additional file 2) and
third (Additional file 3) clinical trials.
First clinical trial
According to our system, among the 286 cases, 0 were for-
mally eligible, 149 were potentially eligible, and 137 were
not eligible. The 30 cases that were identified as eligible
by the experts during the multidisciplinary meetings were
all among the 149 proposed by our system (precision was
0.20; recall was 1.0).
It should be noted that the a posteriori analysis of the
119 cases proposed by our model but not by the MDM
revealed that several were not proposed even if they for-
mally met the eligibility criteria because their Gleason
score was deemed too low. We added an inclusion crite-
rion requiring patients to have a Gleason score superior
or equal to 7. This resulted in 67 cases potentially eligible,
among which were 24 of the 30 actually eligible (precision
was 0.36; recall was 0.80). The six false negative cases had
a Gleason score of 6. Among the 43 false positive, at least
15 were rejected during the MDM because of additional
information not available at the time of pre-screening: 8
because new results indicated that they did not have can-
cer, 3 because too much information was missing and
4 because other elements such as a relatively young age
resulted in proposing a surgical treatment instead of the
clinical trial.
Third clinical trial
According to our system, among the 286 cases, 0 were for-
mally eligible, 34 were potentially eligible, and 252 were
not eligible. The 6 cases that were identified as eligible by
the experts during the multidisciplinary meetings were all
among the 34 proposed by our system (precision was 0.18;
recall was 1.0). Among the 28 false positive, 6 cases were
rejected during the MDM because of additional informa-
tion not available at the time of pre-screening, 5 were
rejected on the basis of information present in their report
Figure 4 The class modeling clinical trial exclusion because at least one of the exclusion criteria has beenmet after classification (here
patients p0, p3 and p6 match the definition).
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Figure 5 The class modeling clinical trial exclusion because at least one of the inclusion criteria failed to be met after classification (here
patients p3, p4 and p5 match the definition).
but erroneously missing in the database, 15 were rejected
because there was no evidence of recurring cancer (not all
the cases examined during the MDM of urology have can-
cer even if most do), and 2 cases were rejected because too
much information was missing.
Adding implicit inclusion criteria for performing the
same post-processing as the first clinical trial resulted in
only 17 potentially eligible cases, among which were 3 of
the 6 identified by the experts (precision was 0.18; recall
was 0.5). This shows that this strategy is not relevant for
this clinical trial.
Discussion
The observed proportion of missing information is com-
patible with results from other studies [22]. Köpcke et al.
compared the information from 706 patient to 351 eligi-
bility criteria from 15 clinical trials. They reported that the
total completeness of EHR data for recruitment purposes
was 35%.
The analysis of the first clinical trial demonstrates that
missing information would have led to the rejection of
all the patients proposed as eligible by the experts during
the multidisciplinary meetings. Our approach identified
potentially eligible patients (149 for the first clinical trial,
and 34 for the third), among which were all the patients
deemed eligible by the experts (30 for the first clinical trial,
and 6 for the third).
This shows that our system confidently rejects non-
eligible cases, which leaves more time to examine the
others during the multidisciplinary meetings. Moreover,
in the first clinical trial, precision can be significatively
improved by adding pragmatic criteria that further dis-
criminate the patients who would not be considered as
eligible even if they meet the pre-screening criteria. Note
that this second step can be kept separate from the for-
mal determination of eligibility but is useful both for the
acceptance of the system by the experts and for maintain-
ing the efficiency of the multidisciplinary meetings.
Missing information can partially be handled even with
reasoning based on negation as failure using ad hoc
conversion between inclusion and exclusion criteria. For
example, the inclusion criterion “absence of ischemic heart
disease” can be converted into the exclusion criterion
“presence of ischemic heart disease”. The former will prob-
ably never bemet because a patient’s record onlymentions
ischemic heart disease when they are present, whereas
the latter will (correctly) only exclude those patients hav-
ing evidence of ischemic heart disease. The problem is
that if “absence of ischemic heart disease” had been an
exclusion criterion, it would likewise have been converted
into the inclusion criterion “presence of ischemic heart
disease” and the system would have (incorrectly, at least
during pre-screening) rejected patients whose record does
not mention the presence nor the absence of ischemic
heart disease. Moreover, a criterion can be an inclusion
criterion for a clinical trial and an exclusion criterion for
another trial, so this strategy is not a general solution to
the problem of missing information.
Reasoning about the conjunction of the eligibility cri-
teria should be handled by OWL, which supports the
open world assumption, rather than by related technolo-
gies such as SWRL which do not. It would be possible
to write a SWRL rule that represents the conjunction of
criteria (cf. formula 3). However, it is impossible to distin-
guish situations where we know that one criterion is not
met from those where we cannot determine if it is met,
because in both cases the rule will not fire.
Applying our criteria modeling design pattern to real
clinical trials and real patients’ data was a manual pro-
cess. The reasoning part of our contribution focused on
combining the status of the eligibility criteria when some
of then can not be determined, not on determining the
statuses themselves. However, both points are of impor-
tance. Our design pattern consisted in modeling each
criterion by two classes representing the certain presence
and the certain absence of the criterion for a patient. As we
have seen in this article, this first modeling part was easy,
can be automated, and addressed the problem of missing
information as one of the causes of patient recruitment
underestimation. When evaluating our system on real
clinical trials and real patients’ data, we had to determine
for each patient whether each criterion was met. This
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required both the occasional decomposition of complex
criteria into logical combinations of simpler conditions,
and the binding with the patients’ data representation in
the local EHR. The first step is generic and rather straight-
forward. It only has to be done once, and can be reused
shared between hospitals or reused if a criterion appears
in several clinical trials. The second step is clearly depen-
dent on the local representation of patients’ data, and was
more difficult and labor-intensive. It also required to write
the functions that process the data, which took a couple
of days for each clinical trial (a portion of the code written
for the first CT could be reused for the second one).
The standardization of data elements would provide
a significant help to the challenge of connecting the
patients’ data with the eligibility criteria. The main stan-
dard organizations (HL7,OpenEHR/EN213606 for clini-
cal care) and CDISC [23] (for clinical research domain)
define their own semantic interoperability framework to
structure and encode data elements with reference ter-
minologies. Moreover recent initiatives have been carried
out to fill the gap between clinical data sources com-
ing from EHRs and Clinical Data Management Systems
(CDMS) including Recruitment Support Systems. For
instance, the Joint Initiative Council was formed as a
partnership between HL7, CDISC, ISO TC 215, IHTSDO,
and CEN TC 251 with the stated goal of increasing col-
laboration between standards organizations based on the
recognition of a common goal of computable seman-
tic interoperability. Clinical Data Acquisition Standards
Harmonization (CDASH) is an initiative that specifies
the unambiguous semantics of a number of common
data elements that are deemed “common” to all trials.
As such, CDASH represents a significant first-step in
achieving cross-trial semantic interoperability. BRIDG
[24] (Biomedical Research Integrated Domain Group)
model which, on one side, contains representations of
clinical research data with underlying mappings to the
HL7 RIM and, on the other side, covers a superset of
the scope defined by CDASH. Currently, several projects
around the world are currently using these standards such
as REUSE [25], EHR4CR [18,26], TRANSFORM [19,20] or
CaBIG [27].
The use of RDF-based (Resource Description Frame-
work) Semantic Web formats (hopefully standardized)
data elements and eligibility criteria would also make
their integration easier. RDF proved to be a key elements
for data integration in more general contexts. Associated
querying and reasoning techniques based on SPARQL
(SPARQL Protocol and RDF Query Language) and SPIN
(SPARQL Inference Notation) for determining the status
of eligibility criteria would have the advantage of having
the rules represented in the same language as the schema
and data to which those rules are attached, as well as hav-
ing sustainable computation performances. On the other
hand, these strategies usually rely on closed-world reason-
ing. Future work should focus on studying the benefits
of such an approach and on determining how well it can
address the problem of missing information.
Potential applications of our approach are not limited
to clinical trials [21]. They cover all clinical decision sit-
uations where some information may be missing. We are
currently adapting this approach for the determination of
pacemaker alerts severity [28]. Electronic health records
and clinical reports have been shown to exhibit large
amounts of redundant information [29,30], but Pakhomov
et al. observed a discordance between patient-reported
symptoms and their (lack of) documentation in the elec-
tronic medical records [31]. They noted that this has
important implications for research studies that rely on
symptom information for patient identification and may
have clinical implications that must be evaluated for
potential impact on quality of care, patient safety, and
outcomes.
Conclusions
We have shown that ignoring the missing information
problem for automatic determination of clinical trial
eligibility led to over-estimate rejection. Systems based on
negation as failure infer that the patient is not eligible if
it cannot be proved that he is eligible, whereas the situ-
ations where it cannot be determined that the patient is
eligible nor that he is not eligible should be identified and
treated separately. A retrospective analysis of 252 patients
with prostate cancer showed that for the four clinical trials
of interest, all the patients had at least one missing value
that resulted in their rejection whereas 62 of them were
actually eligible for at least one of the clinical trials.
We proposed a modeling strategy of eligibility criteria
in OWL that leveraged the open world assumption to
address the missing information problem. Our approach
was able to distinguish a clinical trial for which the patient
is eligible, a clinical trial for which we know that the
patient is not eligible and a clinical trial for which the
patient may be eligible provided that further pieces of
information (which we can identify) can be obtained.
By confidently rejecting some of the non-eligible cases,
our approach leaves more time to examine those requiring
medical expertise during the multidisciplinary meetings.
Additional files
Additional file 1: OWL files for the validation set. The file
clinicalTrial-validation.tgz is a zipped tarball containing a
readme.txt and the OWL files modeling the criteria and the patients’
data from the validation set.
Additional file 2: OWL files for the first clinical trial of evalution set.
The file clinicalTrial-getug14.tgz is a zipped tarball containing
a readme.txt and the OWL files modeling the criteria and the patients’
data for the first clinical trial from the evaluation set.
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Additional file 3: OWL files for the third clinical trial of evalution set.
The file clinicalTrial-getug16.tgz is a zipped tarball containing
a readme.txt and the OWL files modeling the criteria and the patients’
data for the first clinical trial from the evaluation set.
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